Long-term evaluation of the impact of the H1-receptor antagonist Cetirizine on the behavioral, cognitive and psychomotor development of very young children with atopic dermatitis
Long-term evaluation of the impact of the H1-receptor antagonist Cetirizine on the behavioral, cognitive and psychomotor development of very young children with atopic dermatitis
The impact of the prolonged use of cetirizine at high dose (0.25 mg/kg twice a day over 18 mo) on behavior and cognitive ability was examined in a double-blind, randomized, placebo-controlled trial (ETAC—Early Treatment of the Atopic Child) designed to establish whether it was possible to prevent young children (1–2 y old at study entry) with atopic dermatitis from developing asthma. Well-validated and standardized measures of behavior (Behavior Screening Questionnaire) and cognition (McCarthy Scales of Children’s Abilities) were used. In addition, the ages of attainment of psychomotor milestones were established. These measures were taken between an average of 32 and 53 mo of age, both during the study treatment with cetirizine or placebo and after the study treatment had been discontinued. The Behavior Screening Questionnaire was completed at least once on approximately 300 children in each group and on approximately 200 children on five occasions. The McCarthy Scales of Children’s Abilities were administered to approximately 100 in each group at three different times. There were no significant differences between the cetirizine and placebo groups on either of the behavior and cognition measures or in psychomotor milestones during or after the study treatment. These findings suggest that there are no adverse effects on behavior or learning processes associated with the prolonged use of cetirizine in young children with atopic dermatitis.
Abbreviations:
ETAC, Early Treatment of the Atopic Child
BSQ, Behavior Screening Questionnaire
MSCA, McCarthy Scales of Children’s Abilities
GCI, General Cognitive Index
GMQ, Global Medical Questionnaire
251-257
Stevenson, Jim
0c85d29b-d294-43cb-ab8d-75e4737478e1
Cornah, Deborah
de418379-0864-4cd5-826e-7a163f3d5090
Evrard, Philippe
d8ad55bb-e94e-42a1-b11a-89fc8be5a64c
Vanderheyden, Valere
d8c15048-2f2f-4e6d-aa5d-bb982c279862
Billard, Catherine
1596cf68-3922-4336-9617-fc3baa4a56c5
Bax, Martin
cc5e9f6b-3f57-4759-a2e1-b9a441920d88
van Hout, Anne
1603f6b0-a5e9-4e68-a79c-e1d039fcdd83
1 January 2002
Stevenson, Jim
0c85d29b-d294-43cb-ab8d-75e4737478e1
Cornah, Deborah
de418379-0864-4cd5-826e-7a163f3d5090
Evrard, Philippe
d8ad55bb-e94e-42a1-b11a-89fc8be5a64c
Vanderheyden, Valere
d8c15048-2f2f-4e6d-aa5d-bb982c279862
Billard, Catherine
1596cf68-3922-4336-9617-fc3baa4a56c5
Bax, Martin
cc5e9f6b-3f57-4759-a2e1-b9a441920d88
van Hout, Anne
1603f6b0-a5e9-4e68-a79c-e1d039fcdd83
Stevenson, Jim, Cornah, Deborah, Evrard, Philippe, Vanderheyden, Valere, Billard, Catherine, Bax, Martin and van Hout, Anne
(2002)
Long-term evaluation of the impact of the H1-receptor antagonist Cetirizine on the behavioral, cognitive and psychomotor development of very young children with atopic dermatitis.
Pediatric Research, 52 (2), .
(doi:10.1203/01.PDR.0000024060.49308.89).
Abstract
The impact of the prolonged use of cetirizine at high dose (0.25 mg/kg twice a day over 18 mo) on behavior and cognitive ability was examined in a double-blind, randomized, placebo-controlled trial (ETAC—Early Treatment of the Atopic Child) designed to establish whether it was possible to prevent young children (1–2 y old at study entry) with atopic dermatitis from developing asthma. Well-validated and standardized measures of behavior (Behavior Screening Questionnaire) and cognition (McCarthy Scales of Children’s Abilities) were used. In addition, the ages of attainment of psychomotor milestones were established. These measures were taken between an average of 32 and 53 mo of age, both during the study treatment with cetirizine or placebo and after the study treatment had been discontinued. The Behavior Screening Questionnaire was completed at least once on approximately 300 children in each group and on approximately 200 children on five occasions. The McCarthy Scales of Children’s Abilities were administered to approximately 100 in each group at three different times. There were no significant differences between the cetirizine and placebo groups on either of the behavior and cognition measures or in psychomotor milestones during or after the study treatment. These findings suggest that there are no adverse effects on behavior or learning processes associated with the prolonged use of cetirizine in young children with atopic dermatitis.
Abbreviations:
ETAC, Early Treatment of the Atopic Child
BSQ, Behavior Screening Questionnaire
MSCA, McCarthy Scales of Children’s Abilities
GCI, General Cognitive Index
GMQ, Global Medical Questionnaire
This record has no associated files available for download.
More information
Published date: 1 January 2002
Identifiers
Local EPrints ID: 18373
URI: http://eprints.soton.ac.uk/id/eprint/18373
ISSN: 0031-3998
PURE UUID: 2721eff7-cea0-43c4-abf5-844abbe28abd
Catalogue record
Date deposited: 06 Jan 2006
Last modified: 15 Mar 2024 06:04
Export record
Altmetrics
Contributors
Author:
Deborah Cornah
Author:
Philippe Evrard
Author:
Valere Vanderheyden
Author:
Catherine Billard
Author:
Martin Bax
Author:
Anne van Hout
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics